April 2020, Drugs Monitor

(29 April 2020)- Umifenovir- did not shorten the negativity time of SARS-CoV-2 in non ICU patients

April 30, 2020

Umifenovir treatment is not associated with improved outcomes in patients with coronavirus disease 2019: a retrospective study https://doi.org/10.1016/j.cmi.2020.04.026 In a retrospective study, 81 COVID-19 patients were included, with 45 in the umifenovir group and 36 in the control group. Baseline… Continue reading "(29 April 2020)- Umifenovir- did not shorten the negativity time of SARS-CoV-2 in non ICU patients"

(29 April 2020) Remdesivir- Results from interim analysis show 31% faster time to recovery

April 30, 2020

NIH Clinical Trial Shows Remdesivir Accelerates Recovery from Advanced COVID-19 https://www.niaid.nih.gov/news-events/nih-clinical-trial-shows-remdesivir-accelerates-recovery-advanced-covid-19 The interim analysis of results from the trial (known as the Adaptive COVID-19 Treatment Trial, or ACTT), sponsored by the National Institute of Allergy and Infectious Diseases (NIAID) suggest… Continue reading "(29 April 2020) Remdesivir- Results from interim analysis show 31% faster time to recovery"

(29 April 2020) Remdesivir- No statistically significant benefits observed for remdesivir

April 29, 2020

Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31022-9/fulltext The results of first randomised, double-blind, placebo controlled clinical trial assessing the effect of intravenous remdesivir in adults admitted to hospital with severe COVID-19 are reported. The… Continue reading "(29 April 2020) Remdesivir- No statistically significant benefits observed for remdesivir"

(29 April 2020) Novaferon- 3-day reduction of time to SARS-CoV-2 clearance

April 29, 2020

A Novel Protein Drug, Novaferon, as the Potential Antiviral Drug for COVID-19 https://www.medrxiv.org/content/10.1101/2020.04.24.20077735v1 The antiviral effects of Novaferon for COVID-19 patients were in consistence with the laboratory findings. Novaferon inhibited the viral replication in infected cells (EC50=1.02 ng/ml), and protected… Continue reading "(29 April 2020) Novaferon- 3-day reduction of time to SARS-CoV-2 clearance"

(27 April 2020) Remdesivir- potently inhibits SARS-CoV-2 replication in human lung cells (EC50 = 0.01 μM)

April 29, 2020

Remdesivir potently inhibits SARS-CoV-2 in human lung cells and chimeric SARS-CoV expressing the SARS-CoV-2 RNA polymerase in mice. https://www.biorxiv.org/content/10.1101/2020.04.27.064279v1 To rapidly evaluate in vivo efficacy, authors have engineered a chimeric SARS- CoV encoding the viral target of Remdesivir, the RNA-dependent… Continue reading "(27 April 2020) Remdesivir- potently inhibits SARS-CoV-2 replication in human lung cells (EC50 = 0.01 μM)"

(27 April 2020) Update on clinical studies of key drug molecules for COVID 19

April 28, 2020

Update on treatment of COVID-19: ongoing studies between promising and disappointing results. https://www.ncbi.nlm.nih.gov/pubmed/32335561 A compilation of results of trials going on (up to April 15, 2020)for key molecules used in treatment of COVID-19 is presented. Data for Chloroquine, hydroxychloroquine, remdesevir,… Continue reading "(27 April 2020) Update on clinical studies of key drug molecules for COVID 19"

(27 April 2020) Glycyrrhizin – Phytopharmaceuticals- novel therapeutic interventions for COVID-19

April 28, 2020

Pharmacologic perspective: glycyrrhizin may be an efficacious therapeutic agent for COVID-19 https://www.sciencedirect.com/science/article/pii/S0924857920301539?via%3Dihub Glycyrrhizin, a triterpene saponine, is valuable for its various biological functions and pharmacology effects. This article discusses the therapeutic potential of glycyrrhizin for COVID-19 from the perspective of… Continue reading "(27 April 2020) Glycyrrhizin – Phytopharmaceuticals- novel therapeutic interventions for COVID-19"

(26 April 2020) Human recombinant soluble ACE 2 enzyme – hrsACE2 can block early entry of SARS-CoV-2 infections in host cells

April 27, 2020

Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2 https://doi.org/10.1016/j.cell.2020.04.004 Authors report that clinical grade hrsACE2 reduced SARS-CoV-2 recovery from Vero cells by a factor of 1,000–5,000. An equivalent mouse rsACE2 had no effect. They also… Continue reading "(26 April 2020) Human recombinant soluble ACE 2 enzyme – hrsACE2 can block early entry of SARS-CoV-2 infections in host cells"

(23 April 2020) Baricitinib- none of the baricitinib-treated patients required admission to ICU

April 27, 2020

Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7177073/ Baricitinib at 4 mg/day/orally was given to 12 patients with moderate COVID-19. In baricitinib-treated patients no adverse events were recorded and clinical and respiratory parameters significantly improved… Continue reading "(23 April 2020) Baricitinib- none of the baricitinib-treated patients required admission to ICU"

(22 April 2020) Tocilizumab- within 24 h following the tocilizumab infusion, improvement in fever and hypoxaemia observed

April 27, 2020

Case study : a patient with asthma, Covid-19 pneumonia and cytokine release syndrome treated with corticosteroids and tocilizumab https://journals.co.za/content/journal/10520/EJC-1c8cd2727d#abstract_content This report elaborates case of a patient with Covid-19 infection, progressive pneumonia, development of a hyperinflammatory state and cytokine release syndrome… Continue reading "(22 April 2020) Tocilizumab- within 24 h following the tocilizumab infusion, improvement in fever and hypoxaemia observed"

Month: April 2020